Disc Medicine Inc., a clinical-stage biopharmaceutical company, will present data from multiple programs in its hematology portfolio at the European Hematology Association (EHA) 2025 Congress in Milan, Italy, from June 12-15, 2025. They will showcase data from the HELIOS long-term extension trial of bitopertin in erythropoietic protoporphyria, durability data from the Phase 1b study of DISC-0974 in anemia of myelofibrosis, and data from DISC-3405 studies in healthy volunteers.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9450937-en) on May 14, 2025, and is solely responsible for the information contained therein.